Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
Keros Therapeutics, a clinical-stage biopharmaceutical company, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference.
The event will be held on June 10, 2024, at 2:40 p.m. Eastern time. Keros' President and CEO, Jasbir S. Seehra, Ph.D., will present at a fireside chat session.
A live audio webcast of the presentation will be available, with an archived replay accessible on the Keros website for 90 days post-event.
- Participation in a prestigious event like the Goldman Sachs Healthcare Conference increases Keros' visibility and credibility.
- The presentation by CEO Jasbir S. Seehra indicates active leadership involvement in promoting the company’s mission and developments.
- As a clinical-stage biopharmaceutical company, Keros does not yet have marketable products, which may pose risks for investors.
- The press release lacks specific updates on clinical trials or financial performance, which are important for investor confidence.
LEXINGTON, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”), today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Goldman Sachs 45th Annual Healthcare Conference on Monday, June 10, 2024 at 2:40 p.m. Eastern time.
A live audio webcast of the fireside chat presentation will be available at https://cc.webcasts.com/gold006/061024a_js/?entity=139_TKJ7WHC and an archived replay will be accessible in the Investors section of the Keros website at https://ir.kerostx.com for up to 90 days following the conclusion of the event.
About Keros Therapeutics, Inc.
Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. We are a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, we have discovered and are developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros’ lead product candidate, KER-050 (elritercept), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis. Keros’ second product candidate, KER-012 (cibotercept), is being developed for the treatment of pulmonary arterial hypertension and for the treatment of cardiovascular disorders. Keros’ third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases.
Investor Contact:
Justin Frantz
jfrantz@kerostx.com
617-221-6042
FAQ
When will Keros Therapeutics present at the Goldman Sachs Healthcare Conference?
Where can investors watch the Keros presentation?
Who will represent Keros Therapeutics at the Goldman Sachs Healthcare Conference?
What is the significance of Keros Therapeutics' participation in the Goldman Sachs Healthcare Conference?
What is the stock symbol for Keros Therapeutics?
